Versant Capital Management, Inc Avidity Biosciences, Inc. Transaction History
Versant Capital Management, Inc
- $637 Million
- Q2 2025
A detailed history of Versant Capital Management, Inc transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 274 shares of RNA stock, worth $9,326. This represents 0.0% of its overall portfolio holdings.
Number of Shares
274
Previous 207
32.37%
Holding current value
$9,326
Previous $6,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding RNA
# of Institutions
244Shares Held
116MCall Options Held
289KPut Options Held
998K-
Janus Henderson Group PLC London, X011.4MShares$389 Million0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.3MShares$386 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA9.68MShares$330 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.24MShares$315 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.75MShares$298 Million4.23% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.77B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...